Plain-English translation of NCT07514169 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a four-drug combination called Pola-ZR-Glo (polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab) for older adults with large B-cell lymphoma who have never been treated before. The trial wants to see how well this medication works and how safe it is for patients aged 70 and older, especially those who may be too frail or unfit for standard chemotherapy. Researchers will monitor about 30 patients to understand the benefits and side effects of this treatment.
Many older adults with large B-cell lymphoma cannot tolerate traditional chemotherapy because of age-related health challenges. This trial explores whether this new four-drug combination might be a better, gentler option for these patients while still effectively fighting the cancer.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the four-drug treatment combination as part of your cancer care at Ruijin Hospital. Your doctors will monitor your health regularly through blood tests, imaging scans, and clinical visits to see how well the medication is working and to watch for any side effects. The study will track your progress over time to help determine whether this treatment approach is safe and effective for older adults with your type of lymphoma.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Ruijin Hospital
Enrollment target
~30 participants
Started
March 2026
Primary completion
December 2028
Age range
70 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Weili Zhao
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.